Leading sites and pulmonologists to support groundbreaking research
By leveraging relationships with leading pulmonology centers and standalone research facilities, Velocity provides enhanced access to top investigators and specialized patient populations. Many of Velocity’s principal investigators are regional leaders in treating respiratory disorders such as asthma, COPD, and pulmonary fibrosis. This specialized expertise reinforces compliant trial conduct and supports long-term patient assessment.
Velocity also maintains well-established patient databases that include sensitive and hard-to-recruit cohorts. These active practice databases are particularly valuable for rare and orphan disease research programs, as well as for reaching patients who may consider clinical trials as a care option.
In addition to its pulmonology sites, Velocity operates dedicated research centers and general medicine sites that support high-volume trials for more common respiratory conditions, such as asthma and COPD. Velocity will align you with the right patients and investigators in the ideal care setting for your trial. For even the most complex pulmonology research programs, you can trust Velocity to provide reliable enrollment and procedural continuity.
Therapeutic expertise
- Acute Respiratory Distress Syndrome (ARDS)
- Acute Respiratory Infection (ARI)
- Alpha-1 Antitrypsin Deficiency
- Asthma
- Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Rhinosinusitis
- Common Cold
- Cough
- Cystic Fibrosis
- Emphysema
- Eosinophilic Asthma
- Nasal Congestion
- Nasal Polyps
- Non-Cystic Fibrosis Bronchiectasis (NCFB)
- Pulmonary Fibrosis
- Rhinitis
- Rhinoconjunctivitis
- Upper Respiratory Infection (URI)
In the News
Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This study could pave the way for new treatment options in bronchiectasis, and Dr. Watz’s team also served as the central sputum lab in this trial. Article: Article: https://pubmed.ncbi.nlm.nih.gov/39255990/ Recently in Vienna, Dr. Watz was involved in … Read more